AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03496233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]
Description: Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
Study NCT01133405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Oral capsules
Study NCT03294967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: As in group descriptions
Study NCT03294967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E
Description: As in group descriptions
Study NCT01133405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study NCT03473717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic method
Description: * Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~* Insert the hysterometer to measure the uterus depth.~* Locate the uterine depth on the inserter tube.
Study NCT03473717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct method
Description: * Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~* Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity
Study NCT01414101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS CRP Rx or Placebo
Study NCT03145792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seeking Safety
Description: Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
Study NCT03145792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Pathological Gambling
Description: Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
Study NCT00086281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (P)
Description: Placebo Oral Solution
Study NCT00086281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (P)
Description: Placebo Oral Solution
Study NCT04467450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
Study NCT05266872 — intervention group
Intervention type: OTHER
Intervention: Observational study with sample and data collection
Description: Observational study with sample and data collection
Study NCT00512252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Study NCT00512252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT05404347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: NGS is carried out on DNA isolated from paraffin embedded tissue
Study NCT00043017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI/MRS
Description: Serial MRI studies evaluated for prognostic properties related to therapeutic response.
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
Study NCT05877833 — intervention group
Intervention type: OTHER
Intervention: Vibrancy Assessment
Description: Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
Study NCT02985554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
Study NCT01824901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00043017 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gadopentetate dimeglumine
Description: Imaging agent used for contrast enhancement in each of the MRIs.
Study NCT00512252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00512252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02448069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
Study NCT03732807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Induction Dose
Description: Oral tablets taken once daily (QD)
Study NCT03732807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #1
Description: Oral tablets taken QD
Study NCT03732807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #2
Description: Oral tablets taken QD
Study NCT03732807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #3
Description: Oral tablets taken QD
Study NCT04467450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl Prednisolonate
Description: ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
Study NCT01908907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA oil
Description: Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
Study NCT01908907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: (MCT) Control oil
Description: Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
Study NCT03166137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Description: Radiation by carbon dioxide laser
Study NCT03732807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets taken QD
Study NCT00686595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg IV infusion.
Study NCT01184885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD
Description: * Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are \< 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses.
Study NCT01184885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
Study NCT03166137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Device using cooling effect
Study NCT02365116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Description: Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
Study NCT02365116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
Study NCT03337269 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational video
Description: Approximately 7 minute video on the HPV vaccine
Study NCT03337269 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational handout
Description: One page handout on the HPV vaccine
Study NCT03337269 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control
Study NCT00660907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
Study NCT02701777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STDP
Description: Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
Study NCT02701777 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training
Description: The participant will be asked to perform exercises using their hands and arms.
Study NCT02701777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The participant will be asked to perform exercises using their hands and arms.
Study NCT02701777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham STDP
Description: Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
Study NCT02701777 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multisite-STDP
Description: Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
Study NCT02199951 — intervention group
Intervention type: DRUG
Intervention: Dihydroartemisinin and piperaquine
Description: Antimalarial
Study NCT01069263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
Study NCT01069263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMSO
Description: 50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
Study NCT00241631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: 500 u
Study NCT00241631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00241631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline
Description: Theophylline placebo capcule
Study NCT00241631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline placebo capcule
Study NCT02728544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise and blood tests
Description: At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
Study NCT02728544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and blood tests
Description: At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
Study NCT01279629 — intervention group
Intervention type: DRUG
Intervention: Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).
Description: Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
Study NCT03200275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunocatch™ Legionella Urine Antigen Test
Description: A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
Study NCT03998670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prism Glasses
Description: Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
Study NCT03998670 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Prism Glasses
Description: Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
Study NCT04217967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
Study NCT04217967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib
Description: the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
Study NCT04217967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
Study NCT04217967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
Study NCT01089023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
Study NCT01637363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 6 x 2 hours of psychoeducation
Study NCT01376063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9
Study NCT04092881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
Study NCT04092881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
Study NCT01459640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Intra-articular injection; 30mg/2ml; three-weekly injection regimen
Study NCT01459640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells
Description: Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)
Study NCT00567671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal collagen
Description: Corneal collagen cross-linking with riboflavin/UVA light
Study NCT00567671 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham treatment
Study NCT02203383 — intervention group
Intervention type: DEVICE
Intervention: CRT Implantation
Description: Implantation of a biventricular pacemaker or defibrillator.
Study NCT03130660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Ultrasound guidance for central line
Study NCT03871101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.
Study NCT03871101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2780 nm Er,Cr:YSGG Laser
Description: Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
Study NCT03062553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Description: MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
Study NCT03062553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham/MCT
Description: The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
Study NCT03062553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
Study NCT02323204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link for Injured Kids
Description: Psychological First Aid
Study NCT02323204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: So you've been in an accident
Description: Educational materials
Study NCT01894880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early SSC
Description: bonding straight after birth
Study NCT01894880 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: late SSC
Description: bonding after termination of operation
Study NCT03790436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaquik
Description: Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik.
Study NCT03158012 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Microbial Transplant
Description: Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
Study NCT03158012 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Microbial Transplant
Description: Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
Study NCT03754582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral tablets.